Q-omics provides the consensus-scored RNU6-46P profile across patient tissues and cancer cell-line models. RNU6-46P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU6-46P is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, RNU6-46P RNA expression shows 9,032 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, KIRP, and ESCA as cancer lineages where RNU6-46P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-46P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-46P survival associations across molecular data types. RNU6-46P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-46P RNA expression–survival associations across cancer types. High RNU6-46P expression shows unfavorable associations in UVM, COAD, MESO, KICH and PCPG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU6-46P RNA expression.
This table summarizes RNU6-46P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-46P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-46P shows lower tumor expression in KIRP, KICH and CHOL and higher tumor expression in KIRC and THCA. The KIRP box plot shows higher RNU6-46P RNA expression in normal versus tumor tissue (log2 FC = −1.160, t-test p < 0.001).
This table shows molecular features associated with RNU6-46P in patient tissues and cancer cell lines. In patient samples, RNU6-46P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
